Key population brief.
Краткое руководство.
Pathak et al. (2016), PeerJ, DOI 10.7717/peerj.1738; 1-14
Joint United Nations Programme on HIV/AIDS
Journal of Child Psychology and Psychiatry60:5 (2019), pp 500–515
In this review, the editors will investigate the impact of eight WASH interventions in preventing (reducing the risk of) and controlling outbreaks in LMIC, with particular focus on three diseases of current concern to the response community – cholera, Ebola, and Hepatitis E. Additionally, we will ...explore economic outcomes related to WASH interventions within an outbreak
more
Очень часто дети это уязвимая под-группа внутри уже уязвимых групп населения. Поэтому необходимо, чтобы политики, гражданское общество и медицинские работники без...отлагательно обратили свое внимание на проблему борьбы с детским туберкулезом. Дети являются источником развития заболеваний в будущем, а продолжающееся бездействие приводит к потере многих человеческих жизней.
Accessed on 19.07. 2019
more
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
In this article a cluster randomized cross-sectional survey, conducted in Albay Province in the Philippines in April 2016, was used to assess the prevalence of disability and access to support services. This was done with the purpose of generating representative data for local programme development.... A cross-sectional survey was carried out with the WG/UNICEF methodology to examine the prevalence of disabilities, and the accessibility and coverage of relevant services. The aim is for this information to be used for public policy formulation at all levels, as well as to improve communication and advocacy on disabilities.
more
The evidence base for differentiated care for stable patients has grown in recent years. There has been less attention, however, to developing differentiated models of care for patients with advanced or unstable HIV disease. Current clinical guidelines and policies regarding optimal packages of care... for high-risk patients give few or no recommendations about how, by whom, or where they should be delivered for optimal impact.
more
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
This policy brief identifies and explains the main reasons behind the rise of antimicrobial resistance (AMR) associated with improper use of antibiotics in the livestock sector. Focusing on the low- and middle- income country setting, this brief provides recommendations for a deliberated policy stra...tegy aimed to prevent healthcare crisis that could happen as a result of AMR.
more
Previous pandemics have demonstrated that more people could die from the indirect consequences of an outbreak than from the disease itself. As the fight against the pandemic is pushing millions into poverty and hunger, COVID-19 will likely be no different.
Tuberculosis cases, TB deaths
Background paper 10
The Independent Panel for Pandemic Preparedness and Response
May 2021
Global and Regional Data 1 December 2021; The 90–90–90 targets were missed, but not by much. At the end of 2020, 84% of people living with HIV knew their HIV status, 87% of people living with HIV who knew their HIV status were accessing antiretroviral therapy, and 90% of people on treatment were... virally suppressed.
more
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more